IL154913A0 - Composition comprising immunogenic microparticles - Google Patents

Composition comprising immunogenic microparticles

Info

Publication number
IL154913A0
IL154913A0 IL15491301A IL15491301A IL154913A0 IL 154913 A0 IL154913 A0 IL 154913A0 IL 15491301 A IL15491301 A IL 15491301A IL 15491301 A IL15491301 A IL 15491301A IL 154913 A0 IL154913 A0 IL 154913A0
Authority
IL
Israel
Prior art keywords
microparticles
composition
immunogenic microparticles
provides
immunogenic
Prior art date
Application number
IL15491301A
Other languages
English (en)
Original Assignee
Austin Res Inst A & Rmc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR4888A external-priority patent/AUPR488801A0/en
Priority claimed from AUPR4962A external-priority patent/AUPR496201A0/en
Application filed by Austin Res Inst A & Rmc filed Critical Austin Res Inst A & Rmc
Publication of IL154913A0 publication Critical patent/IL154913A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL15491301A 2000-09-14 2001-09-14 Composition comprising immunogenic microparticles IL154913A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR0117A AUPR011700A0 (en) 2000-09-14 2000-09-14 Composition comprising immunogenic virus sized particles (VSP)
AUPR4888A AUPR488801A0 (en) 2001-05-10 2001-05-10 Composition comprising immunogenic virus sized particles (vsp)
AUPR4962A AUPR496201A0 (en) 2001-05-14 2001-05-14 Composition comprising immunogenic virus sized particles (VSP)
PCT/AU2001/001160 WO2002022164A1 (fr) 2000-09-14 2001-09-14 Composition comprenant des microparticules immunogenes

Publications (1)

Publication Number Publication Date
IL154913A0 true IL154913A0 (en) 2003-10-31

Family

ID=27158243

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15491301A IL154913A0 (en) 2000-09-14 2001-09-14 Composition comprising immunogenic microparticles

Country Status (15)

Country Link
US (3) US20040014708A1 (fr)
EP (1) EP1326633B1 (fr)
JP (1) JP5198712B2 (fr)
KR (1) KR20030055262A (fr)
CN (1) CN100446811C (fr)
AT (1) ATE501726T1 (fr)
AU (1) AUPR011700A0 (fr)
CA (1) CA2422575C (fr)
DE (1) DE60144240D1 (fr)
DK (1) DK1326633T3 (fr)
ES (1) ES2363735T3 (fr)
IL (1) IL154913A0 (fr)
NZ (2) NZ524843A (fr)
PT (1) PT1326633E (fr)
WO (1) WO2002022164A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
FR2844514B1 (fr) 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
WO2004104185A1 (fr) * 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation et isolement de lymphocytes t specifiques de l'antigene
WO2005053740A1 (fr) * 2003-12-02 2005-06-16 Bio Matrix Research Inc. Activateur d'immunite et antigene actif obtenu grace a cet activateur
WO2006012695A1 (fr) * 2004-08-04 2006-02-09 Panvax Limited Composition immunogene
KR20080047395A (ko) * 2005-08-25 2008-05-28 다이호야쿠힌고교 가부시키가이샤 Ｔ세포 인식 에피토프 펩티드를 고정화 또는 내포화한생분해성 나노입자
WO2008150276A2 (fr) * 2006-09-26 2008-12-11 The Board Of Regents Of The University Of Texas System Nanoparticules enrobées de virus et leurs utilisations
CN107050440B (zh) 2009-04-01 2021-10-29 迈阿密大学 疫苗组合物和其使用方法
EP2432893B1 (fr) * 2009-05-19 2019-05-01 University Of Miami Compositions, kits et méthodes de présentation d'antigène in vitro, évaluation de l'efficacité d'un vaccin, et évaluation de l'immunotoxicité d'agents biologiques et de médicaments
SG178144A1 (en) * 2009-07-29 2012-03-29 Bernd Helmut Adam Rehm Polymer particles and uses thereof
HUE034247T2 (en) * 2010-11-05 2018-02-28 Novavax Inc Rabies glycoprotein virus-like particles (VLP-K)
US20120189700A1 (en) * 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
CN103857387B (zh) * 2011-06-02 2017-03-15 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2015021390A2 (fr) 2013-08-08 2015-02-12 The Regents Of The University Of California Membranes biologiques s'appuyant sur des nanoparticules pour cibler des pathogènes pour le traitement et le diagnostic de maladies
WO2015143295A2 (fr) 2014-03-20 2015-09-24 The Regents Of The University Of California Compositions d'hydrogel contenant des nanoparticules de liaison ou d'absorption de toxines et leurs utilisations
EP3865139B1 (fr) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Association d'une cancérothérapie et d'une thérapie de contrôle des cytokines pour le traitement du cancer
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2016250570B2 (en) 2015-04-21 2021-07-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2016176041A1 (fr) 2015-04-29 2016-11-03 The Regents Of The University Of California Détoxication à l'aide de nanoparticules
CA3014885A1 (fr) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Association d'une immunotherapie et d'une therapie de controle des cytokines pour le traitement du cancer
CN109200271B (zh) * 2018-11-14 2021-01-29 江南大学 一种蛋白质及其在调控巨噬细胞免疫功能方面的应用
WO2020257315A1 (fr) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Systèmes d'adjuvants présentés par une protéine à antigènes multiples
EP3986447A4 (fr) * 2019-06-18 2023-08-16 Citranvi Biosciences, LLC Protéines porteuses modifiées de manière rationnelle pour vaccins
CN110339350A (zh) * 2019-07-25 2019-10-18 广州中科蓝华生物科技有限公司 一种抗肿瘤的联合用药物组合物及其应用
WO2022026917A1 (fr) * 2020-07-31 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions vaccinales et leurs méthodes d'utilisation
WO2024097307A1 (fr) * 2022-11-01 2024-05-10 Lupagen, Inc. Dispositifs et méthodes de traitement extracorporel de cellules

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4035316A (en) * 1975-11-24 1977-07-12 California Institute Of Technology Cell specific, variable density, polymer microspheres
US4170685A (en) * 1976-03-29 1979-10-09 California Institute Of Technology Polyvinyl pyridine microspheres
US4157323A (en) * 1976-06-09 1979-06-05 California Institute Of Technology Metal containing polymeric functional microspheres
US4247434A (en) * 1978-12-29 1981-01-27 Lovelace Alan M Administrator Process for preparation of large-particle-size monodisperse
US4438239A (en) * 1981-03-30 1984-03-20 California Institute Of Technology Microsphere coated substrate containing reactive aldehyde groups
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4828984A (en) * 1986-04-11 1989-05-09 Flow Cytometry Standards Corporation Composition, synthesis and use of simulated cells
US6338853B1 (en) * 1987-04-23 2002-01-15 Jean-Claude Bystryn Anti-cancer vaccine
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5219577A (en) * 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
US5178882A (en) * 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5665582A (en) * 1990-10-29 1997-09-09 Dekalb Genetics Corp. Isolation of biological materials
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US5928647A (en) * 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP1181937A3 (fr) * 1994-08-09 2004-02-04 Cytrx Corporation Vaccin contenant des acides nucléiquées et adjuvant de vaccin
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DE69526260T2 (de) 1994-11-15 2002-10-17 Powderject Vaccines, Inc. Methode zur induktion der humoralen und zellulären immunantwort durch intrazelluläre zufuhr von peptidbeschichteten mikropartikeln
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
AU714584B2 (en) * 1995-07-21 2000-01-06 Brown University Research Foundation A method for gene therapy using nucleic acid loaded polymeric microparticles
CA2257408A1 (fr) * 1996-07-10 1998-01-15 Lisbeth Illum Compositions convenant a la distribution de genes dans des cellules epitheliales
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
WO1998033487A1 (fr) * 1997-01-30 1998-08-06 Chiron Corporation Utilisation de microparticules contenant un antigene adsorbe dans le but de stimuler les reponses immunitaires
ES2248914T3 (es) 1997-08-29 2006-03-16 Corixa Corporation Agentes bioactivos encapsulados de liberacion rapida que permiten inducir o potenciar una respuesta inmunitaria y metodos para utilizar los mismos.
US6001333A (en) 1997-09-12 1999-12-14 See; Jackie R. Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging
WO1999036090A1 (fr) 1998-01-16 1999-07-22 The Johns Hopkins University Administration par voie orale de vaccins d'acides nucleiques au moyen de complexes particulaires
SE9800615D0 (sv) 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
JP4601823B2 (ja) 1998-09-01 2010-12-22 メリオン リサーチ スリー リミテッド 経口ワクチン組成物
CA2361421A1 (fr) * 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium et procedes de fabrication et d'utilisation associes
CA2362578A1 (fr) * 1999-02-09 2000-08-17 Kam Leong Vaccins anti-tumeurs
WO2000054730A2 (fr) * 1999-03-18 2000-09-21 The President & Fellows Of Harvard College Compositions de vaccins contre le papillomavirus humain et procedes associes
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
JP2003501379A (ja) 1999-06-02 2003-01-14 ナノファーマ アーゲー ガン治療のための薬剤を充填したナノパーティクルの使用
EP1118331A1 (fr) 2000-01-21 2001-07-25 I.D.M. Immuno-Designed Molecules Méthode pour augmenter la présentation d'antigène exogène par les cellules humaines présentatrices d'antigène et complexes de microparticules opsonisées pour appliquer cette méthode
EP1265598B1 (fr) 2000-03-22 2006-08-02 The Secretary of State for Defence Composition pharmaceutique pour administration sur des surfaces muqueuses
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
FR2859909B1 (fr) * 2003-09-22 2007-09-07 Biomerieux Sa Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation
WO2005046722A2 (fr) * 2003-11-05 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugues de nanoparticules-antigenes carbohydrate et utilisation comme agents anti-metastatiques dans le traitement du cancer
JP4772693B2 (ja) * 2003-12-11 2011-09-14 ヴァックスデザイン・コーポレーション 免疫治療組成物、その製造方法及び使用方法
WO2008051245A2 (fr) * 2005-12-02 2008-05-02 Novartis Ag Nanoparticules destinees a etre utilisees dans des compositions immunogenes
US8021689B2 (en) * 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
WO2007100699A2 (fr) * 2006-02-24 2007-09-07 Novartis Ag Microparticules contenant un polymère biodégradable et un polysaccharide cationique pour emploi dans des compositions immunogènes
JP2009541281A (ja) * 2006-06-20 2009-11-26 シーエムピー セラピューティクス リミテッド キチンマイクロ粒子を含む組成物およびそれらの医学的使用
US8333972B2 (en) * 2006-08-16 2012-12-18 Temple University Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions
WO2008082439A2 (fr) * 2006-08-28 2008-07-10 Duke University Nanoparticules fluorescentes spécifiques d'un antigène
AT504160A1 (de) 2006-09-11 2008-03-15 Ralf Dr Kircheis Verwendung einer mehrkomponenten-tumorvakzine
WO2008118861A2 (fr) * 2007-03-23 2008-10-02 The University Of North Carolina At Chapel Hill Nanoparticules organiques d'une dimension discrète et d'une forme spécifique conçues pour provoquer une réponse immunitaire
MX350501B (es) * 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
US9107858B2 (en) * 2007-12-05 2015-08-18 Wisconsin Alumni Research Foundation Dendritic cell targeting compositions and uses thereof
EP2250189A4 (fr) 2008-02-26 2012-07-04 Univ California Glycopeptides et procédés pour les préparer et les utiliser
JP2012515722A (ja) 2009-01-20 2012-07-12 ノースウェスタン ユニバーシティ 抗原特異的寛容の誘導のための組成物および方法

Also Published As

Publication number Publication date
JP5198712B2 (ja) 2013-05-15
WO2002022164A1 (fr) 2002-03-21
ES2363735T3 (es) 2011-08-12
US20100136043A1 (en) 2010-06-03
US8846026B2 (en) 2014-09-30
KR20030055262A (ko) 2003-07-02
CA2422575A1 (fr) 2002-03-21
CN1630531A (zh) 2005-06-22
US20120082725A1 (en) 2012-04-05
US20040014708A1 (en) 2004-01-22
EP1326633A1 (fr) 2003-07-16
DE60144240D1 (de) 2011-04-28
JP2004507566A (ja) 2004-03-11
AUPR011700A0 (en) 2000-10-05
ATE501726T1 (de) 2011-04-15
CA2422575C (fr) 2015-04-28
US8287877B2 (en) 2012-10-16
EP1326633B1 (fr) 2011-03-16
NZ524843A (en) 2004-11-26
EP1326633A4 (fr) 2006-05-24
NZ535851A (en) 2006-04-28
DK1326633T3 (da) 2011-07-04
PT1326633E (pt) 2011-06-29
CN100446811C (zh) 2008-12-31

Similar Documents

Publication Publication Date Title
IL154913A0 (en) Composition comprising immunogenic microparticles
WO2005037190A3 (fr) Vaccins multiplex
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2004032829A3 (fr) Compositions immunostimulantes et procedes de stimulation d'une reponse immune
SG170127A1 (en) Vaccine compositions comprising a saponin adjuvant
EP1594536A4 (fr) Vaccin contre la grippe contenant un adjuvant
MY125202A (en) Vaccine
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
WO2000061761A3 (fr) Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
WO2006071989A3 (fr) Methodes de declenchement, d'accentuation et de maintien de reponses immunitaires contre des epitopes restreints du cmh de classe i a des fins prophylactiques ou therapeutiques
WO2001097841A3 (fr) Qs-21 et il-12 utilises comme combinaison d'adjuvants
DE60136563D1 (de) Salmonella vakzine
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2003053338A3 (fr) Nouveaux antigenes rev, tat, et nef chimeriques
WO2005012538A3 (fr) Vaccination acceleree
WO2004058188A3 (fr) Compositions vaccinales et procedes
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
MY127452A (en) Vaccines.
AU2002342949A1 (en) Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other
WO2002032455A3 (fr) Vaccin
IL193391A0 (en) Influenza antigens, vaccine compositions, and related methods